Cargando...
Use of Eculizumab for Active Antibody-Mediated Rejection that Occurs Early Post-Kidney Transplantation: A Consecutive Series of 15 Cases
BACKGROUND: Active antibody-mediated rejection (AMR) that occurs during the amnestic response within the first month post-transplant is a rare but devastating cause of early allograft loss after kidney transplant. Prior reports of eculizumab treatment for AMR have been in heterogeneous patient group...
Guardado en:
| Publicado en: | Transplantation |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6699919/ https://ncbi.nlm.nih.gov/pubmed/30801549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TP.0000000000002639 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|